Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s share price traded up 4.3% during trading on Friday . The stock traded as high as $26.70 and last traded at $24.63. 235,447 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 275,257 shares. The stock had previously closed at $25.75.

Several equities analysts have commented on the company. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price objective on the stock. in a research report on Tuesday, August 29th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. ValuEngine raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Credit Suisse Group set a $24.00 price objective on Intellia Therapeutics and gave the company a “buy” rating in a research report on Saturday, June 3rd. Finally, Cann reaffirmed a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $25.43.

The firm’s market cap is $891.97 million. The company’s 50-day moving average is $22.21 and its 200 day moving average is $22.21.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. Intellia Therapeutics’s revenue for the quarter was up 40.5% compared to the same quarter last year. On average, analysts expect that Intellia Therapeutics, Inc. will post ($1.78) earnings per share for the current fiscal year.

In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.80% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at $101,000. Nisa Investment Advisors LLC acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at $134,000. Bank of Montreal Can grew its stake in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares in the last quarter. Nationwide Fund Advisors grew its stake in shares of Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares in the last quarter. Finally, IHT Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics in the first quarter valued at $117,000. 46.52% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/23/intellia-therapeutics-inc-ntla-trading-4-3-higher.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.